Mesoblast Limited vs Mitsubishi UFJ Financial Group Inc. Common Stock — how do they compare? Mesoblast Limited trades at $14.24 (market cap $1.75B), while Mitsubishi UFJ Financial Group Inc. Common Stock trades at $22.38 (market cap $249.48B). The key difference: Mitsubishi UFJ Financial Group Inc. Common Stock is far larger — about 142.6× Mesoblast Limited's market cap, and Mitsubishi UFJ Financial Group Inc. Common Stock pays a 2.4% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Mitsubishi UFJ Financial Group Inc. Common Stock for 0 Days on average.
| MESO | MUFG | |
|---|---|---|
Market Cap | $1.75B | $249.48B |
Volume | 239,027 | 4,008,160 |
Sector | Health | Financials |
52-Week High | $20.96 | $24.13 |
52-Week Low | $13.19 | $14.62 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $1.83B | $28.96T |
Dividend Yield | — | 2.4% |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Mitsubishi UFJ Financial Group is a Japanese financial services company providing banking, lending, securities, and asset management services. Its businesses serve individuals, companies, and institutions worldwide.
Read more on MUFG →